Pfizer stock climbs as first quarter earnings, revenue come ahead of estimates

Pfizer (NYSE: PFE) shares rose 3% in premarket trading Wednesday after the drugmaker reported Q1 earnings and revenue that beat analyst estimates.

Earnings per share (EPS) stood at $0.82, exceeding the consensus estimates of $0.53. Revenue came in at $14.9 billion, also above the consensus projection of $14.04 billion.

Meanwhile, adjusted research and development (R&D) expenses were reported at $2.48 billion, below the expected $2.66 billion. However, adjusted selling, informational, and administrative (SI&A) expenses were slightly higher at $3.45 billion compared to the forecast of $3.39 billion.

For the full year 2024, Pfizer forecasts an EPS range of $2.15 to $2.35, against a consensus of $2.21. Revenue projections range from $58.5 to $61.5 billion, compared to the anticipated $60 billion.

This guidance includes expected revenues of approximately $8 billion from Comirnaty and Paxlovid ($5 billion and $3 billion, respectively) and around $3.1 billion from legacy Seagen products.

“We delivered strong performance in our non-COVID product portfolio in the first quarter of 2024, including increased revenue from several of our recent commercial launches and acquired products, as well as robust year-over-year growth for several key in-line brands, namely the Vyndaqel family, Eliquis, and the Prevnar family,” said Dr. Albert Bourla, Chairman and CEO.

“Overall, I am encouraged by a well-executed quarter, setting the tone for the year. Pfizer’s commercial leadership is focused on data-driven opportunities across several key growth brands, both in the U.S. and internationally, and we intend to build on this positive momentum in the quarters ahead.”

By Vahid Karaahmetovic

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge